key: cord-0285447-ruo53mja
authors: Cao, Longxing; Coventry, Brian; Goreshnik, Inna; Huang, Buwei; Park, Joon Sung; Jude, Kevin M.; Marković, Iva; Kadam, Rameshwar U.; Verschueren, Koen H.G.; Verstraete, Kenneth; Walsh, Scott Thomas Russell; Bennett, Nathaniel; Phal, Ashish; Yang, Aerin; Kozodoy, Lisa; DeWitt, Michelle; Picton, Lora; Miller, Lauren; Strauch, Eva-Maria; Halabiya, Samer; Hammerson, Bradley; Yang, Wei; Benard, Steffen; Stewart, Lance; Wilson, Ian A.; Ruohola-Baker, Hannele; Schlessinger, Joseph; Lee, Sangwon; Savvides, Savvas N.; Garcia, K. Christopher; Baker, David
title: Robust de novo design of protein binding proteins from target structural information alone
date: 2021-09-05
journal: bioRxiv
DOI: 10.1101/2021.09.04.459002
sha: 2e84fac67aaba919b11d6026b1169b2ef22c9ed7
doc_id: 285447
cord_uid: ruo53mja

The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dimensional structure of the target remains an outstanding challenge. We describe a general solution to this problem which starts with a broad exploration of the very large space of possible binding modes and interactions, and then intensifies the search in the most promising regions. We demonstrate its very broad applicability by de novo design of binding proteins to 12 diverse protein targets with very different shapes and surface properties. Biophysical characterization shows that the binders, which are all smaller than 65 amino acids, are hyperstable and bind their targets with nanomolar to picomolar affinities. We succeeded in solving crystal structures of four of the binder-target complexes, and all four are very close to the corresponding computational design models. Experimental data on nearly half a million computational designs and hundreds of thousands of point mutants provide detailed feedback on the strengths and limitations of the method and of our current understanding of protein-protein interactions, and should guide improvement of both. Our approach now enables targeted design of binders to sites of interest on a wide variety of proteins for therapeutic and diagnostic applications.

Protein interactions play critical roles in biology, and general approaches to 68 disrupt or modulate these with designed proteins would have huge impact. While 69 empirical laboratory selection approaches starting from very large antibody, DARPIN or 70 other protein scaffold libraries can generate binders to protein targets, it is difficult at the 71 outset to target a specific region on a target protein surface, and to sample the full 72 space of possible binding modes. Computational methods can target specific target 73 surface locations and provide a more principled and potentially much faster approach to 74 binder generation than random library selection methods, as well as insight into the 75 fundamental properties of protein interfaces (which must be understood for design to be 76 successful). Most current methods for computationally designing proteins to bind to a 77 target surface utilize information derived from native complex structures on specific 78 sidechain interactions or protein backbone placements optimal for binding 1-3 . 79 Computational docking of antibody scaffolds with varied loop geometries has yielded 80 binders, but the designed binding modes have rarely been validated with high-resolution 81 structures 4 . Binders have been generated starting from several computationally 82 identified hot-spot residues, which were then used to guide the positioning of naturally 83 occurring protein scaffolds 5 . However, for many target proteins, there are no obvious 84 pockets or clefts on the protein surface into which a small number of privileged 85 sidechains can be placed, and guidance by only a small number of hotspot residues 86 limits the approach to a small fraction of possible interaction modes. 87 Design Method 88 We sought to develop a general approach to design of high affinity binders to 89 arbitrary protein targets that addresses two major challenges. First, in the general case, 90 there are no clear sidechain interactions or secondary structure packing arrangements 91 that can mediate strong interactions with the target; instead there are a very large 92 number of individually very weak possible interactions. Second, the number of ways of 93 choosing from these numerous weak interactions to incorporate into a single binding 94 protein is combinatorially large, and any given protein backbone is unlikely to be able to 95 simultaneously present sidechains that can encompass any preselected subset of these 96 interactions. To motivate our approach, consider the simple analogy of a very difficult 97 climbing wall with only a few good footholds or handholds distant from each other. 98 Previous "hotspot" based approaches correspond to focusing on routes involving these 99 footholds/handholds, but this greatly limits the possibilities and there may be no way to 100 connect them into a successful route. An alternative is to first, identify all possible 101 handholds and footholds, no matter how poor, second, have thousands of climbers 102 select subsets of these, and try to climb the wall, third, identify those routes that were 103 most promising, and fourth, have a second group of climbers explore them in detail. 104 Following this analogy, we devised a multi-step approach to overcome the above two 105 challenges by 1) enumerating a large and comprehensive set of disembodied sidechain 106 interactions with the target surface, 2) identifying from large in silico libraries of protein 107 backbones those that can host many of these sidechains without clashing with the 108 target, 3) identifying recurrent backbone motifs in these structures, and 4) generating 109 and placing against the target a second round of scaffolds containing these interacting 110 motifs (Fig. 1a) . Steps 1 and 2 search the space very widely, while steps 3 and 4 111 intensify search in the most promising regions. We describe and motivate each step in 112 the following paragraphs. For docking against the rotamer interaction field, it is desirable to have a very 132 large set of protein scaffold options, as the chance that any one scaffold can house 133 many interactions is small. The structure models of these scaffolds must be quite 134 accurate so that the positioning is correct. Using fragment assembly 7 , piecewise 135 fragment assembly 8 , and helical extension 9 , we designed a large set of miniproteins 136 ranging in length from 50 to 65 amino acids containing larger hydrophobic cores than 137 previous miniprotein scaffold libraries 1 , which makes the protein more stable and more 138 tolerant to introduction of the designed binding surfaces. 84,690 scaffolds spanning 5 139 different topologies with structural metrics predictive of folding were encoded in large 140 oligonucleotide arrays and 34,507 were found to be stable using a high-throughput 141 proteolysis based protein stability assay 10 .

142 143 We experimented with several approaches for docking these stable scaffolds 144 against the target structure rotamer interaction field, balancing overall shape 145 complementarity with maximizing specific rotamer interactions. The most robust results 146 were obtained using direct low resolution shape matching 11 followed by grid based 147 refinement of the rigid body orientation in the RIF (RIFDock). This resulted in better 148 Rosetta binding energies (ddGs) and packing (contact molecular surface, see below) 149 after sequence design than shape matching alone with PatchDock ( Fig. 1b red and   150 green), and more extensive non polar interaction with the target than hierarchical 151 search without PatchDock shape matching 6 (Extended Data Fig. 1) .

Because of the loss in resolution in the hashing used to build the RIF, and the 154 necessarily approximate accounting for interactions between sidechains (see methods), 155 we found that evaluation of the RIF solutions is considerably enhanced by full 156 combinatorial optimization using the Rosetta forcefield, allowing the target sidechains to 157 repack and the scaffold backbone to relax. Full combinatorial sequence optimization is 158 quite CPU intensive, however, and to enable rapid screening through millions of 159 alternative backbone placements, we developed a rapid pre-screening method using 160 Rosetta to identify promising RIF docks. We found that including only hydrophobic 161 amino acids, using a reduced set of rotamers than in standard Rosetta design 162 calculations, and a more rapidly computable energy function sped design more than 10-163 fold while retaining a strong correlation with results after full sequence design (next 164 paragraph); this pre-screen (referred to as the "Predictor" below) substantially improved 165 the binding energies and shape complementarity of the final designs as far more RIF 166 solutions could be processed (Extended Data Fig. 2) . per-position weighted Rosetta binding energy; around 2,000 motifs were selected for 205 each target. These motifs, which are privileged because they contain a much greater 206 density of favorable side chain interactions with the target than the rest of the designs, 207 were then used to guide another round of docking and design. Scaffolds from the 208 library were superimposed on the privileged motifs, the favorable-interacting motif 209 residues transferred to the scaffold, and the remainder of the scaffold sequence 210 optimized to make further interactions with the target, allowing backbone flexibility to 211 increase shape complementarity with the target (Fig. 1a) . Interface metrics for the 212 designs based on the resampling protocol were considerably improved relative to those 213 of the designs from the broad searching stage (Fig. 1b) . The designs with the most 214 favorable protein folding and protein interface metrics from both the broad searching 215 and resampling stages were selected for experimental validation. We expressed the highest affinity combinatorially-optimized binders for each 271 target in E.coli for more detailed structural and functional characterization. All of the 272 designs were in the soluble fraction, and could be readily purified by nickel-NTA 273 chromatography. All had circular dichroism spectra consistent with the design model, 274 and most (9 out of 13) were stable at 95 °C (Fig. 2d) . The binding affinities for the 275 targets were assessed by biolayer interferometry, and found to range from 300 pM to 276 900 nM (Fig. 2c and Extended Data Table 2 ). The sequence mapping data report on 277 the residues on the design critical for binding, but only weakly on the region of the target 278 bound. We investigated this using a combination of binding competition experiments, 279 biological assays, and structural characterization of the complexes. For the nine targets 280 for which these were available, this characterization suggested binding modes 281 consistent with the design models, as described in the following paragraphs. Platelet Derived Growth Factor-BB (PDGF-BB), insulin, insulin growth factor-1 (IGF-1) 293 and Angiopoietin 1 (Ang1) on yeast suggest that the binders for TrkA, PDGFR, InsulinR, 294 IGF1R and Tie2 bind to the targeted sites (Extended Data Fig. 8) , consistent with the 295 computational design models. The receptor tyrosine kinase binders as monomers are 296 all expected to be antagonists, and we tested the effect on signaling through TrkA, 297 FGFR2 and EGFR of the cognate binders on cells in culture. Strong inhibition of 298 signaling by the native agonists was observed in all three cases (Fig. 3a-c, Extended   299 Data Fig. 9 and Extended Data Fig. 10) .

Binding of IL-7 to the IL-7α receptor subunit leads to recruitment of the γc 302 receptor, forming a tripartite cytokine-receptor complex crucial to several signaling 303 cascades leading to the development and homeostasis of T and B cells 28 . We obtained 304 a picomolar affinity binder for IL-7Rα targeting the IL-7 binding site, and found that it 305 blocks STAT5 signaling induced by IL-7 (Fig. 3d) . We also obtained binders to CD3δ, 306 one of the subunits of the T-cell receptor, and the signaling molecule TGF-β, which play 307 critical roles in immune cell development and activation (Fig. 2) . Fig. 12c,d) , 335 suggesting that the binder binds the hemagglutinin at the targeted site. We also 336 designed binders to the prokaryotic pathogen protein VirB8 which belongs to the type IV 337 secretion system of Rickettsia typhi, which is the causative agent of murine typhus 25 . 338 We selected the surface region composed of the second and the third helices of VirB8, 339 and obtained binders with 500 pM affinity (Fig. 2) . The designed binding proteins are all very small proteins (<65 amino acids), and 353 many are 3-helix bundles. To evaluate their target specificity, we tested the highest 354 affinity binder to each target for binding to all other targets. There was very little cross 355 reactivity (Fig. 4a) , likely due to their quite diverse surface shapes and electrostatic 356 properties (Fig. 4b) . Consistent with previous observations with affibodies 40 Table 3 ). The H3 binder binds to the shallow groove of the stem region 367 of HK68/H3 HA in the crystal structure as designed; the Cα root-mean-square deviation 368 (rmsd) over the entire miniprotein binder is 1.42 Å using the HA as the alignment 369 reference ( Fig. 5a and Extended Data Fig. 13) . The binder makes extensive 370 hydrophobic interactions with HA and almost all of the designed interface side chain 371 configurations are recapticulated in the crystal structure (Fig. 5a) . There is a clear 372 reorientation of the oligosaccharide at Asn38 compared with the unbound HK68/H3 373 structure ( Fig. 5a and Extended Data Fig. 11 ; this has been observed in HK68/H3 374 structures bound with stem region neutralizing antibodies 33,34 ), consistent with the 375 higher binding affinity for a deglycosylated variant (N38D) than for wild type H3 HA 376 (A/Hong Kong/1/1968) in BLI assays ( Fig. 2 and Extended Data Fig. 12) . The crystal 377 structure of the TrkA binder in complex with TrkA was very close to the design model 378 (Fig. 5b) . After aligning the crystal structure and design model on TrkA, the Cα rmsd 379 over the entire miniprotein binder is 2.41 Å, and over the two interfacial binding helices 380 1.20 Å. The crystal structures of the FGFR2 binder by itself (Extended Data Fig. 14a ) 381 and in complex with the third Ig-like domain of FGFR4 (Fig. 5c) (Fig 5b,c) . The binding interface partially overlaps 388 with the native ligand binding sites of nerve growth factor (NGF) and fibroblast growth 389 factor (FGF), however, the detailed sidechain interactions are entirely different in the 390 designed and native complexes (Extended Data Fig. 15a,b) . For IL-7Rα, the crystal 391 structure of the monomer is close to that of the design, with a Cα rmsd of 0.63 Å 392 (Extended Data Fig. 14b ) and the co-crystal structure with IL-7Rα also matches with 393 the design model closely, with a Cα rmsd of 2.2 Å using IL-7Rα as the reference (Fig   394   5d ). Both the de novo IL-7Rα binder and the native IL-7 use two helices to bind with IL-395 7Rα, but the binding orientations are totally different (Extended Data Fig. 15c) . Further 396 highlighting the accuracy of the protein interface design method, the cryoEM structures 397 of the SARS-CoV-2 binders LCB1 and LCB3 in complex with the virus are also nearly 398 identical to the design models, with Cα rmsd of 1.27 Å and 1.9 Å respectively 37 (Fig. 5e) . 399 While we were not able yet to solve structures for the remainder of the designs, the high 400 resolution sequence footprinting (Fig. 2b, Extended Data Fig. 20 

Massively parallel de novo protein design for targeted 595 therapeutics

Computational design of trimeric influenza-neutralizing 597 proteins targeting the hemagglutinin receptor binding site

De novo design of potent and selective mimics of IL-2 and IL-15

Principles for computational design of binding antibodies

Proceedings of the National Academy of Sciences of the United States of 603

Computational design of proteins targeting the conserved 605 stem region of influenza hemagglutinin

De novo design of a fluorescence-activating beta-barrel

Principles for designing ideal protein structures

Sampling of Structure and Sequence Space of Small Protein 612 Folds

Perturbing the energy landscape for improved packing during 614 computational protein design

Global analysis of protein folding using massively parallel 617 design, synthesis, and testing

PatchDock 620 and SymmDock: servers for rigid and symmetric docking

Modular repeat protein sculpting using rigid helical junctions

Proceedings of the National Academy of Sciences of the United States of 624

Protein sequence optimization with a pairwise 626 decomposable penalty for buried unsatisfied hydrogen bonds

Crystal structure of 629 nerve growth factor in complex with the ligand-binding domain of the TrkA 630 receptor

Crystal 632 structures of two FGF-FGFR complexes reveal the determinants of ligand-633 receptor specificity

Crystal structure of a truncated epidermal growth factor 636 receptor extracellular domain bound to transforming growth factor alpha

Structures of a platelet-derived growth factor/propeptide 639 complex and a platelet-derived growth factor/receptor complex

Higher-Resolution Structure of the Human Insulin Receptor 643

Multi-Modal Inclusion of the Insert Domain

How ligand binds to the type 1 insulin-like growth factor receptor

Crystal structures of the Tie2 receptor ectodomain and the 648 angiopoietin-2-Tie2 complex

Structural and biophysical studies of 651 the human IL-7/IL-7Ralpha complex

epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment

Proceedings of the National Academy of Sciences of the United States of 656

Ternary complex of transforming growth factor-beta1 reveals 658 isoform-specific ligand recognition and receptor recruitment in the superfamily

Cross-neutralization of influenza A viruses mediated by a 662 single antibody loop

Structural Insight into How Bacteria Prevent Interference 664 between Multiple Divergent Type IV Secretion Systems

The intrinsic contributions of tyrosine, serine, glycine and 667 arginine to the affinity and specificity of antibodies

Cell signaling by receptor tyrosine kinases

Modulation of Signaling Mediated by TSLP and IL-672 7 in Inflammation, Autoimmune Diseases, and Cancer

Evolution and ecology of influenza A viruses

Comparison of complete amino acid sequences and 678 receptor-binding properties among 13 serotypes of hemagglutinins of influenza A 679 viruses

Structure of 681 influenza haemagglutinin at the pH of membrane fusion

Antibody recognition of a highly conserved influenza virus 684 epitope

A neutralizing antibody selected from plasma cells that binds to 686 group 1 and group 2 influenza A hemagglutinins

Group 2 Influenza A Viruses

Potent peptidic fusion inhibitors of influenza virus

A small-molecule fusion inhibitor of influenza virus is 694 orally active in mice

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Ultrapotent miniproteins targeting the receptor-binding domain 698 protect against SARS-CoV-2 infection and disease in mice

De novo design of modular and tunable protein 700 biosensors

Affibody molecules as engineered protein drugs